$30 million helps Grove go after hard-to-treat cancers

24 April 2025

US biotech Grove Biopharma has secured $30 million in a series A round to move its lead program targeting advanced prostate cancer into clinical trials and expand development of its synthetic biology platform, known as Bionic Biologics.

The round was led by DCVC Bio and included Eli Lilly (NYSE: LLY), InVivium Capital, Walder Ventures and Portal Innovations, the Chicago-based incubator where Grove got its start.

The financing will support the company’s push toward an investigational new drug application for its androgen receptor signaling program in castrate-resistant prostate cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK